- LIVE QUOTES
- LEARN
- HELP
More from Webull
Our Partners
Nasdaq
Wall Street JournalEN
C
CTMX
Cytomx Therapeutics Inc
5.43
-0.04-0.73%After Hours: 5.49 +0.06 +1.11%19:32 02/20 EST
OPEN/PREV CLOSE5.34/5.47
TODAY RANGE5.33-5.56
VOL1.91M
MARKET CAP920.03M
52 WEEK RANGE0.4000-6.35
AVG VOL (3M)3.02M
% TURNOVER1.13%
TURNOVER--
P/E (TTM)13.49
% RANGE4.11%
EPS(TTM)0.4026
P/E(FORWARD)-128.1870
P/B8.35
BVPS0.6506
DIVIDEND--
P/S3.149
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP813.59M
SHARES OUTSTANDING169.44M
NEXT EARNINGS03/04-03/09
FREE FLOAT149.83M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·4d ago
CytomX Therapeutics (CTMX) Receives a Buy from Barclays
TipRanks·02/06 13:26
Oppenheimer Remains a Buy on CytomX Therapeutics (CTMX)
Dow Jones·02/04 16:13
CytomX Therapeutics Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones·02/04 14:23
CytomX Therapeutics Price Target Raised to $10.00/Share From $8.00 by Barclays
Dow Jones·02/04 14:23
CytomX Therapeutics Is Maintained at Overweight by Barclays
Benzinga·02/04 14:14
Barclays Maintains Overweight on CytomX Therapeutics, Raises Price Target to $10
Reuters·02/04 11:16
CYTOMX THERAPEUTICS <CTMX.O>: BARCLAYS RAISES TARGET PRICE TO $10 FROM $8
TipRanks·02/04 10:51
CytomX Therapeutics price target raised to $10 from $8 at Barclays
TipRanks·02/04 09:11
Wall Street Analysts Are Bullish on Top Healthcare Picks
Reuters·02/04 06:59
U.S. RESEARCH ROUNDUP- Ametek, Coca-Cola, Pepsico
Simply Wall St·02/04 02:34
A Look At CytomX Therapeutics (CTMX) Valuation After Optimistic Analyst Target Hikes On Phase 1 Cancer Data
Same Industry
Name/Symbol
Change%
Price